HONG KONG – China's drug authority is upscaling the Marketing Authorization Holder (MAH) mechanism pilot, which is seen as a boon for drug innovation in the country. The CFDA released another notice regarding the pilot MAH mechanism in the country which clarified details on the responsibilities of the authorization holders and license transferring.